Non-exclusive rebate agreement for spironolactone

Summary

The tender concerns a non-exclusive rebate agreement for the medicinal product spironolactone (only strength 25 mg, ATC C03DA01) for the period 01/07/2026 to 30/06/2028, with an option to extend the contract once by 12 months. DAK-Gesundheit intends to conclude rebate agreements with as many interested pharmaceutical companies as possible. The machine-readable notice did not include precise qualification, suitability or compliance requirements; these must be checked in the procurement documents.